Europeiska unionen - estniska - EMA (European Medicines Agency)

pierre fabre medicament - propranoloolvesinikkloriid - hemangioom - beetablokaatorid - hemangiol is indicated in the treatment of proliferating infantile haemangioma requiring systemic therapy: , life- or function-threatening haemangioma,, ulcerated haemangioma with pain and/or lack of response to simple wound care measures,, haemangioma with a risk of permanent scars or disfigurement. , it is to be initiated in infants aged 5 weeks to 5 months.

Europeiska unionen - estniska - EMA (European Medicines Agency)

pfizer europe ma eeig - tofacitinib - artriit, reumatoidartriit - immunosupressandid - rheumatoid arthritistofacitinib in combination with methotrexate (mtx) is indicated for the treatment of moderate to severe active rheumatoid arthritis (ra) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying antirheumatic drugs (dmards) (see section 5. tofacitinib can be given as monotherapy in case of intolerance to mtx or when treatment with mtx is inappropriate (see sections 4. 4 ja 4. psoriatic arthritistofacitinib in combination with mtx is indicated for the treatment of active psoriatic arthritis (psa) in adult patients who have had an inadequate response or who have been intolerant to a prior disease modifying antirheumatic drug (dmard) therapy (see section 5. ulcerative colitistofacitinib is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent (see section 5. tofacitinib is indicated for the treatment of active polyarticular juvenile idiopathic arthritis (rheumatoid factor positive [rf+] or negative [rf-] polyarthritis and extended oligoarthritis), and juvenile psoriatic arthritis (psa) in patients 2 years of age and older, who have responded inadequately to previous therapy with disease modifying antirheumatic drugs (dmards). tofacitinib can be given in combination with methotrexate (mtx) or as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. ankylosing spondylitistofacitinib is indicated for the treatment of adult patients with active ankylosing spondylitis (as) who have responded inadequately to conventional therapy.

Estland - estniska - Ravimiamet

inibsa dental s.l. - artikaiin+epinefriin (adrenaliin) - süstelahus - 40mg+0,005mg 1ml 1.8ml 50tk

Estland - estniska - Ravimiamet

alcon farmaceutika d.o.o. - proksümetakaiin - silmatilgad, lahus - 5mg 1ml 15ml 1tk

Estland - estniska - Ravimiamet

septodont - artikaiin+epinefriin (adrenaliin) - süstelahus kolbampullis - 40mg+0,005mg 1ml 1.7ml 400tk; 40mg+0,005mg 1ml 1.7ml 200tk; 40mg+0,005mg 1ml 1.7ml 50tk

Estland - estniska - Ravimiamet

inibsa dental s.l. - artikaiin+epinefriin (adrenaliin) - süstelahus - 40mg+0,01mg 1ml 1.8ml 100tk; 40mg+0,01mg 1ml 1.8ml 50tk

Estland - estniska - Ravimiamet

septodont - artikaiin+epinefriin (adrenaliin) - süstelahus kolbampullis - 40mg+0,01mg 1ml 1.7ml 50tk

Estland - estniska - Ravimiamet

laboratoire innotech international - raud(ii)glükonaat+mangaanglükonaat+vaskglükonaat - suukaudne lahus - 5mg+0,133mg+0,07mg 1ml 10ml 20tk

Europeiska unionen - estniska - EMA (European Medicines Agency)

yes pharmaceutical development services gmbh - doksorubitsiini vesinikkloriid - breast neoplasms; ovarian neoplasms; multiple myeloma; sarcoma, kaposi - antineoplastilised ained - celdoxome pegylated liposomal is indicated in adults:as monotherapy for patients with metastatic breast cancer, where there is an increased cardiac risk. or treatment of advanced ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen. in combination with bortezomib for the treatment of progressive multiple myeloma in patients who have received at least one prior therapy and who have already undergone or are unsuitable for bone marrow transplant. for treatment of aids-related kaposi’s sarcoma (ks) in patients with low cd4 counts (< 200 cd4 lymphocytes/mm3) and extensive mucocutaneous or visceral disease. celdoxome pegylated liposomal may be used as first-line systemic chemotherapy, or as second line chemotherapy in aids-ks patients with disease that has progressed with, or in patients intolerant to, prior combination systemic chemotherapy comprising at least two of the following agents: a vinca alkaloid, bleomycin and standard doxorubicin (or other anthracycline).